Vykat XR — United Healthcare
hyperphagia associated with Prader-Willi Syndrome
Initial criteria
- Diagnosis of hyperphagia associated with Prader-Willi Syndrome
- AND Prader-Willi Syndrome is confirmed by genetic testing
- AND Patient is at least 4 years of age and older
Reauthorization criteria
- Documentation of positive clinical response to Vykat XR therapy
Approval duration
Initial 12 months; Reauth 12 months.